160 related articles for article (PubMed ID: 9703325)
1. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.
Pederson RA; White HA; Schlenzig D; Pauly RP; McIntosh CH; Demuth HU
Diabetes; 1998 Aug; 47(8):1253-8. PubMed ID: 9703325
[TBL] [Abstract][Full Text] [Related]
2. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide.
Pauly RP; Demuth HU; Rosche F; Schmidt J; White HA; Lynn F; McIntosh CH; Pederson RA
Metabolism; 1999 Mar; 48(3):385-9. PubMed ID: 10094118
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance.
Augstein P; Berg S; Heinke P; Altmann S; Salzsieder E; Demuth HU; Freyse EJ
Diabetes Obes Metab; 2008 Sep; 10(10):850-61. PubMed ID: 17970756
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.
Pospisilik JA; Stafford SG; Demuth HU; Brownsey R; Parkhouse W; Finegood DT; McIntosh CH; Pederson RA
Diabetes; 2002 Apr; 51(4):943-50. PubMed ID: 11916911
[TBL] [Abstract][Full Text] [Related]
5. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
Pospisilik JA; Martin J; Doty T; Ehses JA; Pamir N; Lynn FC; Piteau S; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2003 Mar; 52(3):741-50. PubMed ID: 12606516
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.
Pospisilik JA; Stafford SG; Demuth HU; McIntosh CH; Pederson RA
Diabetes; 2002 Sep; 51(9):2677-83. PubMed ID: 12196458
[TBL] [Abstract][Full Text] [Related]
8. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.
Kieffer TJ; McIntosh CH; Pederson RA
Endocrinology; 1995 Aug; 136(8):3585-96. PubMed ID: 7628397
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.
Balkan B; Kwasnik L; Miserendino R; Holst JJ; Li X
Diabetologia; 1999 Nov; 42(11):1324-31. PubMed ID: 10550416
[TBL] [Abstract][Full Text] [Related]
10. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats.
Hinke SA; Gelling RW; Pederson RA; Manhart S; Nian C; Demuth HU; McIntosh CH
Diabetes; 2002 Mar; 51(3):652-61. PubMed ID: 11872663
[TBL] [Abstract][Full Text] [Related]
11. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.
Sudre B; Broqua P; White RB; Ashworth D; Evans DM; Haigh R; Junien JL; Aubert ML
Diabetes; 2002 May; 51(5):1461-9. PubMed ID: 11978643
[TBL] [Abstract][Full Text] [Related]
12. Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.
Jia X; Elliott R; Kwok YN; Pederson RA; McIntosh CH
Diabetes; 1995 May; 44(5):495-500. PubMed ID: 7729605
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
[TBL] [Abstract][Full Text] [Related]
14. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
[TBL] [Abstract][Full Text] [Related]
15. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.
Lynn FC; Pamir N; Ng EH; McIntosh CH; Kieffer TJ; Pederson RA
Diabetes; 2001 May; 50(5):1004-11. PubMed ID: 11334402
[TBL] [Abstract][Full Text] [Related]
16. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
17. Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. A novel kinetic approach.
Pauly RP; Rosche F; Wermann M; McIntosh CH; Pederson RA; Demuth HU
J Biol Chem; 1996 Sep; 271(38):23222-9. PubMed ID: 8798518
[TBL] [Abstract][Full Text] [Related]
18. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
19. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors.
Demuth HU; McIntosh CH; Pederson RA
Biochim Biophys Acta; 2005 Aug; 1751(1):33-44. PubMed ID: 15978877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
